MYC/Bcl-2共表达在弥漫大B细胞淋巴瘤预后判断中的意义研究

杨帆; 钱申贤; 赵亦菲; 安娜

doi:10.16462/j.cnki.zhjbkz.2016.07.018

MYC/Bcl-2共表达在弥漫大B细胞淋巴瘤预后判断中的意义研究

doi: 10.16462/j.cnki.zhjbkz.2016.07.018

南京医科大学附属杭州医院血液科, 浙江杭州 310006

基金项目:

杭州市卫生局科技计划项目（2013Z03）

详细信息

作者简介:
杨帆(1987-),男,浙江杭州人,在读硕士研究生。主要研究方向:恶性淋巴瘤的危险分层及临床治疗。

中图分类号: R733.41;R181
计量
- 文章访问数: 373
- HTML全文浏览量: 77
- PDF下载量: 26
- 被引次数: 0
出版历程
- 收稿日期: 2015-12-13
- 修回日期: 2016-03-17

Analysis of the co-expression of MYC/Bcl-2 in prognosis of diffuse large B cell lymphoma

Department of Hematology, Hangzhou affiliated Hospital of Nanjing Medical University, Hangzhou 310006, China

摘要

摘要: 目的分析MYC/Bcl-2蛋白共表达与弥漫大B细胞淋巴瘤临床特点及预后的关系，以探讨MYC/Bcl-2蛋白共表达在弥漫大B细胞淋巴瘤中的意义。方法对经病理确诊的89例弥漫大B细胞淋巴瘤患者的淋巴瘤组织标本进行MYC和Bcl-2蛋白表达的免疫组化检查，对是否应用利妥昔单抗、原发部位、年龄、性别、Ann Arbor分期、国际预后指数、免疫组化Hans分型、Ki-67表达率以及MYC/Bcl-2蛋白共表达等因素进行无进展生存期的单因素比较，对具有统计学差异的因素纳入多因素回归分析。结果 MYC/Bcl-2共表达患者为29例，占32.6%，单因素分析是否应用利妥昔单抗、年龄≥60岁、分期Ⅲ~Ⅳ期、国际预后指数3~5分、MYC/Bcl-2共表达为不良预后因素（均有P<0.05），是否应用利妥昔单抗、年龄≥60岁、分期Ⅲ~Ⅳ期、国际预后指数3~5分、MYC/Bcl-2共表达经多因素回归分析具有统计学意义（均有P<0.05）。结论 MYC/Bcl-2共表达为弥漫大B细胞淋巴瘤的独立预后危险因素。
- 淋巴瘤 /
- 预后 /
- 流行病学方法
Abstract: Objective To analyze the relationship between co-expression of MYC/Bcl-2 proteins and clinical features and prognosis of diffuse large B-cell lymphoma(DLBCL), so as to explore the significance of MYC/Bcl-2 protein co-expression in DLBCL. Methods The immunohistochemical examination of MYC/Bcl-2 protein expression was conducted for lymphoma tissue samples of 89 cases of DLBCL patients who were pathologically confirmed. Next, a single factor comparison with progression free survival was made to such factors as whether to apply rituximab, primary sites,ages,genders,Ann Arbor stage,international prognostic index,immunohistochemistry Hans typing, Ki-67 expression and MYC/Bcl-2 protein co-expression. Then the factors having a statistically significant difference were included for multi-factor regression analysis. Results There were 29 cases of MYC/Bcl-2 co-expression patients, accounting for 32.6%. Through single factor comparison, the factors of whether to apply rituximab, age> 60 years, stages Ⅲ-Ⅳ, international prognostic index =3-5 scores, and MYC/Bcl -2 coexpression were adverse prognostic factors (all P<0.05); and the factors of whether to apply rituximab, age>60 years, stages Ⅲ-Ⅳ, international prognostic index=3-5 scores, and MYC/Bcl-2 co-expression had statistical significance (all P<0.05) through multi-factor regression analysis. Conclusions MYC/Bcl-2 co-expression is an independent prognostic risk factor for DLBCL.
- Lymphoma /
- Prognosis /
- Epidemiologic methods

HTML全文

参考文献(19)

Gatter K, Warnke RA. Diffuse large B-cell lymphoma. In: Jaffe E S, Stein H, Vardiman J W, eds. World Health Organization classification of tumors: pathology and genetics of tumors of haematopoietic and lymphoid tissues [M]. Lyon: IARC Press, 2001.

李小秋,李甘地,高子芬,等. 中国淋巴瘤亚型分布:国内多中心性病例10 002例分析 [J]. 诊断学理论与实践, 2012,11(2):111-115.

中国医学学会血液学分会,中国抗癌协会淋巴瘤专业委员会. 中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版) [J]. 中华血液学杂志, 2013,34(9):816-819

German O,Marita Z,Wolfram K, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL [J]. Blood, 2010,116(23):4916-4925

Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t (14; 18) and 8q24/c-MYC rearrangement [J]. Haematologica, 2007, 92(10):1335-1342

Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [J]. J Clin Oncol, 2012, 30(28):3460-3467

Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab [J]. J Clin Oncol, 2010, 28(20):3360-3365.

Foot NJ, Dunn RG, Geoghegan H, et al. Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin's lymphoma: a single centre's experience [J]. J Clin Patho, 2011,64(9):802-808

Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/Bcl2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program [J]. Blood, 2013, 121(20):4021-4031

Perry AM, Crockett D, Dave BJ, et al. B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and burkitt lymphoma: study of 39 cases [J]. Br J Haematol, 2013, 162(1):40-49

Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and Bcl2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone [J]. J Clin Oncol, 2012, 30(28):3452-3459

Rantanen S, Monni O, Joensuu H, et al. Causes and consequences of Bcl2 overexpression in diffuse large B-cell lymphoma [J]. Leuk Lymphoma, 2001,42(5):1089-1098

Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J]. Blood, 2004,103(1):275-282

Wilson WH, Dunleavy K, Pittaluga S, et al. Phase Ⅱ study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers [J]. J Clin Oncol, 2008,26(16):2717-2724

Choi WW , Weisenburger DD, Greiner T C, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy [J]. Clin Cancer Res, 2009,15(17):5494-5502

García-Suárez J, Flores E, Callejas M,et al. Two weekly dose-adjusted DA -EPOCH-like chemotherapy with high dose dexamehasone plus rituximab (DA-EDOCHl4-R)in poor-prognostic untreated diffuse large B-cell lymphoma [J].Br J Haematal, 2013,160(4):510-514.

Pittaluga S, Shovlin M, Pack S, et al. Concurrent Expression Of MYC/Bcl-2 protein in newly diagnosed DLBCL is Not associated with an inferior survival following EPOCH-R therapy [J]. Blood, 2013, 122(21): 3029-9.

张江,孔佩艳. 蛋白质芯片在恶性肿瘤研究中的应用 [J]. 中华疾病控制杂志, 2010,14(3):263-265.

崔国惠,吴要功. 下一代测序技术在淋巴瘤中的应用 [J]. 临床血液学杂志, 2014,27(6):931-935.

施引文献

资源附件(0)

访问统计